Correction

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

N Engl J Med 2006; 354:2200May 18, 2006

Article

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (Original Article, N Engl J Med 2005:353;2462 - 2476) . On page 2473 in Table 4, the percentage of patients in Active Ulcerative Colitis Trial (ACT) 2 receiving 10 mg of infliximab who had antibodies against double-stranded DNA should have read 6.0, rather than 60.0, as printed. We regret the error.

Citing Articles (1)

Citing Articles

1. 1

   Filomena Morisco, Fabiana Castiglione, Antonio Rispo, Tommaso Stroffolini, Roberto Vitale, Stefano Sansone, Rocco Granata, Ambrogio Orlando, Riccardo Marmo, Gabriele Riegler, Maurizio Vecchi, Livia Biancone, Nicola Caporaso. (2011) Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Digestive and Liver Disease 43, S40-S48
   CrossRef